independent of other known predictors in adults with heart failure. [7] [8] [9] In this population, the presence of EOV may even predict adverse outcomes more robustly than either peak VO 2 or V E /VCO 2 . 9, 10 The known hemodynamic consequences of the Fontan procedure suggest that EOV may be prevalent in this population, and 1 prior study reported EOV in 21 of 36 young patients with Fontan physiology. 11 Our primary objective was to provide a larger perspective on the prevalence, cross-sectional demographic and clinical correlates, and longitudinal prognostic power of EOV in single ventricle Fontan patients.
Methods

Subject Identification
We identified consecutive patients who had clinically indicated ramp cycle ergometry CPET between January 1, 2000, and April 30, 2013, at Boston Children's Hospital and had previously undergone a Fontan procedure (all types, with or without open fenestration). Data collection and analysis were limited to patients born after April 30, 1997 (ie, aged ≥16 years as of April 30, 2013) . Exclusion criteria were 2-ventricle repair or transplantation between the time of initial Fontan and baseline CPET. Baseline CPET was defined as the first cycle CPET during the time period of study. We did not limit the analysis to patients with evidence of maximal effort because EOV can be assessed on submaximal tests. There was no statistically significant difference in the prevalence of EOV among the subset of patients with submaximal CPET (n=46/253 had respiratory exchange ratio, <1.05 and peak heart rate (HR), <80% predicted; 41.3% had EOV versus 36.7% in those with maximal tests; P=0.61). Results of sensitivity analysis excluding submaximal tests were equivalent to the overall sample, including for variables measured at peak exercise such as peak VO 2 , and are not presented. The study was approved by the Boston Children's Hospital Institutional Review Board, and the requirement for informed consent was waived.
Demographic data, including age at the time of CPET, underlying cardiac diagnosis and previous interventions, medication use, and medical comorbidities, were extracted from the medical record. Available laboratory data and cardiac imaging within 2 years of CPET, as well as invasive hemodynamic studies within 5 years of CPET, were also obtained. The primary outcome of interest was death or cardiac transplantation. A secondary combined outcome of interest included death, transplant, or incident nonelective hospitalization for cardiovascular or Fontan-related events (ie, arrhythmia, heart failure, ascites, protein-losing enteropathy, plastic bronchitis, or thromboembolism).
Data Analysis
CPET involved symptom-limited cycle ergometry using a continuous ramp protocol with electrocardiographic monitoring and breathby-breath expiratory gas analysis (CardiO 2 exercise testing system; Medical Graphics, Minneapolis, MN). CPET data included rest and peak oxygen saturation (sO 2 %), blood pressure and HR, peak VO 2 defined as the highest 30-s average value during the test, VO 2 at the anaerobic threshold (AT; assessed by V-slope method), V E /VCO 2 slope before AT, peak respiratory exchange ratio, peak O 2 pulse, end-tidal partial pressure of CO 2 at AT, and spirometry variables (FEV 1 ; forced vital capacity [FVC]; FEV 1 :FVC). To assess potential artifactual confounding of CPET data assessment because of the oscillatory nature of EOV, we repeated the analysis using (1) 2 alternative definitions of peak VO 2 : average VO 2 over the final 30 and 60 s of the test and (2) various measures of V E /VCO 2 : V E /VCO 2 slope over the entire test, V E /VCO 2 at AT, and minimum V E /VCO 2 during the test. Each approach yielded consistent results and only the analysis using standard definitions is presented.
EOV was assessed using custom software developed in MATLAB R2013a (MathWorks, Natick, MA) plotting time and V E on the xand y-axes, respectively. EOV was defined as regular oscillations with amplitude >15% of average V E during the exercise test, which were present for >60% of total exercise duration ( Figure 1 ). 12 Data were analyzed through automated detection of oscillations, with userreview and manual selection as necessary. EOV was determined for each test by 2 investigators (A.S.N. and A.R.O.) blinded to subject identifying information and outcome; disagreements were adjudicated by consensus between the investigators.
Statistical Analysis
The 2-sided unpaired Student t test (or Wilcoxon rank-sum test, as appropriate for distribution) and Fischer exact test were used to analyze continuous and categorical variables, respectively, between EOV and non-EOV groups. Continuous variables are presented as mean±SD. The log-rank test was used to perform univariate survival analysis, stratified by EOV status. Baseline time was defined as the date of the initial CPET, and follow-up continued until the first clinical event (either transplantfree survival or the secondary combined outcome), or was censored at the most recent clinical follow-up when outcome status was known.
The relatively low number of events for the primary combined outcome limited the ability to adjust for multiple covariates without variance inflation; therefore, we present only univariate survival analysis of the relationship between EOV and transplant-free survival. We used multivariable Cox regression with the secondary combined outcome as the dependent variable and EOV as the independent variable of interest, adjusting for the following covariates simultaneously: age, New York Heart Association functional class (NYHA FC), V E / VCO 2 slope, % predicted FVC, % predicted peak HR, and peak VO 2 . Statistical analyses were performed with SAS 9.3 (SAS Institute, Cary, NC) and GraphPad Prism (GraphPad Software, La Jolla, CA). A 2-sided P value <0.05 was considered statistically significant.
Results
Demographic and Clinical Correlates of EOV
Among the 253 patients who met inclusion criteria, 95 demonstrated EOV (37.5%). Patients with EOV were younger (18.8±9.0 versus 21.7±10.1 years; P=0.02) and smaller (height 156.2±14.7 versus 161.3±14.3 cm; P=0.01; weight 53.0±18.6 versus 59.1±17.2 kg; P=0.01; Table 1 ). There were no significant differences between patients with and without EOV in race, sex, medication use, underlying diagnosis, ventricular morphology, heterotaxy, current Fontan type, or presence of Fontan fenestration at the time of CPET. No patients were on inhaled or parenteral pulmonary vasodilators.
At the time of initial CPET, patients with EOV tended to have worse NYHA FC (P=0.02). Among patients with available testing, those with EOV had slightly lower cardiac index. There were no other statistically significant differences in laboratory measures of end-organ function, noninvasive measures of ventricular function, or hemodynamics between patients with and without EOV ( Table 1) . 
EOV and CPET Results
Exercise test results are given in Table 2 . Baseline HR, sO 2 %, and systolic blood pressure were similar in patients with and without EOV. Peak HR was lower in patients with EOV (74.7±14.1 versus 79.4±13.6% predicted; P=0.01), but there was no statistically significant difference in peak sO 2 % or blood pressure. Although peak VO 2 was similar for those with and without EOV (59.7±14.3 versus 61.0±16.0% predicted; P=0.52 and 23.5±6.9 versus 22.9±7.0 mL/kg per minute; P=0.53), EOV was associated with a lower peak work rate (96±44 versus 113±41 W; P<0.001); this difference in peak work persisted when expressed relative to normative data (61.5±16.5 versus 66.6±17.8% predicted; P=0.03) or indexed to body surface area (63±19 versus 69±19 W/m 2 ; P=0.002).
AT was also achieved earlier among those with EOV (34.3±8.8 versus 36.7±9.1% of predicted peak VO 2 ; P=0.05). There were no differences in baseline FEV 1 , FVC, or FEV 1 :FVC ratio ( Table 3 ). Exercise ventilatory response did differ between the groups, however. Patients with EOV had higher V E /VCO 2 slope (36.8±6.9 versus 33.7±5.7; P=0.0002). Peak V E (50.8±16.9 versus 54.6±17.3 L/min; P=0.10) was similar, but patients with EOV had higher peak respiratory rate (46.8±14.3 versus 40.8±10.4 bpm; P=0.0002) and lower tidal volume (1.2±0.5 versus 1.4±0.5 L; P=0.003). Baseline demographic, clinical, invasive hemodynamic, and noninvasive imaging data. Continuous variables are presented as mean±SD, whereas categorical variables are presented as % (n). For categorical variables without complete data for all subjects, the number of subjects with available data is noted (n/n with available data). For laboratory and catheterization variables, the number of subjects with available data is noted next to the variable name (n=number of subjects with available data with absent, present EOV, respectively). Data for pulmonary vascular resistance are presented excluding patients with incomplete data on cardiac index, Fontan pressure or PA wedge pressure. For continuous variables, P values were calculated using an unpaired t test for most variables, but the Wilcoxon rank-sum test was used for non-normally distributed variables (cardiac index, PVR, Qp:Qs, and TPG). There were 6 events among the 150 patients who did not demonstrate EOV, all primary deaths. Among those with EOV (n=90), there were 16 events: 13 primary deaths, 2 transplants followed by death, and 1 transplant without death. EOV was associated with higher risk of death or transplant over the full study period (hazard ratio, 3.9; 95% CI, 1.5-10.0; P=0.002; Figure 2A ; Table 4 ).
Survival Analysis, EOV as a Predictor of Death or Transplantation
Survival Analysis, EOV as a Predictor of Death, Transplantation, or Nonelective Cardiovascular Hospitalization
NYHA FC, age, % predicted peak HR, % predicted peak VO 2 , and EOV (hazard ratio, 1.8; 95% CI, 1.1-3.0; P=0.01; Figure 2B) were statistically significant univariate predictors of the secondary combined outcome (n=62 events), but V E /VCO 2 slope was not (hazard ratio, 1.03; 95% CI, 0.99-1.08; P=0. 15) . FVC tended to be inversely associated with the outcome, but this was not statistically significant (per +10% predicted; hazard ratio, 0.9; 95% CI, 0.7-1.0; P=0.08). The only independent predictors of the combined outcome of death, transplantation, or nonelective cardiovascular hospitalization in a multivariable model inclusive of all covariates were EOV (hazard ratio, 2.0; 95% CI, 1.2-3.6; P=0.01), NYHA FC (>I; hazard ratio, 4.0; 95% CI, 2.1-7.4; P<0.001), and % predicted peak HR (per +10%; hazard ratio, 0.77; 95% CI, 0.62-0.95; P=0.01). Conversely, age and peak VO 2 were not independent predictors in this multivariable model.
Discussion
These data demonstrate that EOV is common among patients who have had the Fontan procedure and predicts increased risk of death or heart transplant. This aligns with previous studies demonstrating the use of CPET, [13] [14] [15] [16] [17] [18] and specifically EOV, [6] [7] [8] [19] [20] [21] [22] [23] [24] [25] as a tool to predict outcomes in patients with heart failure.
EOV is thought to be due to aberrant respiratory autoregulation, which involves carotid body and medullary chemodetection of arterial P a O 2 , P a CO 2 , and pH. 22 Feedback loop instability may generate the wide variability in ventilation characteristic of EOV. Proposed mechanisms include (1) delayed information transfer because of reduced cardiac output, 8 (2) increased gain because of heightened chemosensitivity to P a CO 2 and P a O 2 , 26 and (3) reduced system damping because of baroreflex impairment. 22 The Fontan circulation presents a prime substrate for EOV, given the intrinsically limited cardiac output augmentation, altered chemosensitivity, 27 and dampened baroreflex responses. 28 There was no association between EOV and peak oxygen uptake , which stands in contrast to studies of EOV in acquired heart failure where EOV has consistently been found to correspond to lower aerobic capacity. [6] [7] [8] 20, 29 A previous study reporting on EOV in a group of young (average age, 12.3 years) Japanese total cavopulmonary anastomosis patients reported a sample of Fontan patients with, on average, normal Ventilatory data from baseline cardiopulmonary exercise test. Data are presented as mean±SD. Statistical comparisons were made using the unpaired t test for most variables, but Wilcoxon rank-sum test was used for peak RER, which was not normally distributed. bpm indicates breaths per minute; EOV, exercise oscillatory ventilation; FVC, forced vital capacity; FEV 1 , forced expiratory volume in 1 s; RER, respiratory exchange ratio; RR, respiratory rate; V E , minute ventilation; and V T , tidal volume. peak VO 2 ; EOV was associated with higher peak VO 2 (112% versus 103% predicted, P=0.02, multivariable P=0.047). 11 The authors hypothesized that EOV might represent a compensatory mechanism enabling better use of the respiratory pump to augment cardiac output. That study also reported that EOV was associated with younger age and smaller body size. Interestingly, despite equivalent peak VO 2 in our study, patients with EOV achieved a significantly lower workload. This was partly because of body size and age, but an association remained even after expressing workload as a % of predicted values or indexed to body surface area. One explanation might be that a larger proportion of cardiac output (oxygen consumption divided by oxygen delivery, per the Fick principle) is used to support muscles involved in ventilation because of increased demand in the setting of EOV and ventilatory inefficiency. This is further evinced by the association between EOV and ventilatory inefficiency (V E /VCO 2 ) because patients with EOV required higher minute ventilations to remove accumulating waste products of metabolism. We have previously shown, in another sample of patients with Fontan circulation, that both low FVC and high V E /VCO 2 are associated with lower peak VO 2 . 30 In this study, EOV was associated with younger age and, likely as a consequence of this, smaller body size. This may be because of ongoing maturation of ventilatory regulation through adolescence. [31] [32] [33] Although the small number of events precludes definitive analysis, the available data suggest that the clinical relevance of EOV is unaffected by this unexpected association: EOV remained a significant predictor of the secondary outcome after adjustment for age.
EOV was a statistically significant predictor of death or transplant or nonelective cardiovascular hospitalization even after adjustment for NYHA FC, peak VO 2 , and other covariates. The only other statistically significant predictors after equivalent adjustment were NYHA FC and peak HR.
Notably, V E /VCO 2 slope was not associated with the primary or secondary combined outcome. Previous studies of Fontan patients have reported V E /VCO 2 slope to be a poor predictor of outcomes. Ventilatory inefficiency is pervasive and thought not to be closely related to the severity of heart failure, but rather, to reflect a combination of VQ mismatch intrinsic to a nonpulsatile pulmonary circulation and right-to-left shunt via venovenous collaterals, a patent fenestration or pulmonary arteriovenous malformations. 34 More notable is the tenuous relationship between peak VO 2 and the outcomes of interest. Peak VO 2 is closely linked to functional class; in our sample, peak VO 2 was not a significant predictor of death or transplant or nonelective cardiovascular hospitalization after adjustment for NYHA FC.
Given the basis of EOV in alterations of cardiopulmonary physiology and abnormal central and peripheral chemosensitivity, it is somewhat surprising that variables suggestive of residual right-to-left shunting (hypoxemia and hemoglobin concentration) did not correspond with EOV. This may be related to the chronic, lifelong nature of congenital heart disease and alterations in chemosensitivity related to prolonged cyanosis in childhood and throughout life. An alternative explanation might be that right-to-left shunting has conflicting effects: while it lowers P a O 2 and raises P a CO 2 , it also augments systemic stroke volume.
Although these data support a clinical role for EOV as an independent prognostic tool for patients with single ventricle Fontan physiology, further evaluation is merited to explore the use of combining biomarkers and dynamic physiological variables to increase the power of risk assessment, as has been done for adults with acquired heart failure. [35] [36] [37] [38] Investigators are actively exploring other predictors of poor outcome for Fontan patients, including creatinine, MELD-XI (Model for End-stage Liver Disease eXcluding INR), and other composite clinical scores. [39] [40] [41] Because EOV represents an acute physiological response and is potentially modifiable, 42 it may provide additive information when used in conjunction with static measures of chronic disease to help guide clinical decision making.
Recent evidence suggests that EOV may be modifiable by exercise training or medical therapy in heart failure. 43, 44 The development of exercise training programs for patients after the Fontan procedure, perhaps in tandem with inspiratory muscle training, could prove beneficial to the relief of morbidity and mortality. EOV may eventually be a useful outcome measure for studies of the effect of such therapies, but this will require a better physiological understanding and definition of longitudinal test characteristics.
These results must be interpreted in the context of the study design. First, our results are applicable to the Fontan population, but other types of congenital heart disease could presumably also be associated with a high prevalence of EOV and this could add to the importance of this analysis. Second, only patients who were referred for and able to perform cycle CPET testing were included. These data do not permit direct inference on the significance of EOV in Fontan patients performing staged or treadmill protocols. Third, EOV has heterogeneous definitions (which result in different prevalence estimates), and there are no data on which definition best reflects underlying physiology or predicts outcomes. Furthermore, although EOV is currently defined dichotomously (present or absent), it may represent an extreme case of a spectrum, with current definitions ignoring milder oscillations that may be clinically significant despite being less readily apparent. Assessment of EOV as a continuous variable, or with more attention to the predictive value of the duration, timing, or size of oscillations, may provide further prognostic information for these patients. Robust automated techniques for identifying and reporting EOV (as currently available for V E /VCO 2 ) would enhance the likelihood of clinical application; this has proved challenging, but efforts are ongoing to identify suitable algorithms. 45 Finally, although the results are highly statistically significant, the analysis is based on a relatively small number of events (n=22 for the primary outcome). This limits application of multivariable adjustment; furthermore, validation in an independent sample is needed to support the robustness of our findings.
In summary, EOV is common in the Fontan population and independently predicts incident death or transplant. Additional studies are needed to identify optimal definitions, physiological underpinnings, and the role of this finding in clinical management among patients with a Fontan circulation.
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